A 42-year-old woman from Mumbai presents with a 3-week history of persistent cough, fever, and progressive dyspnea. She recovered from confirmed COVID-19 infection 6 weeks ago (RT-PCR positive, mild symptoms, home-managed). Current RT-PCR is negative, but she remains symptomatic. High-resolution CT chest shows bilateral lower lobe predominant ground-glass opacities with traction bronchiectasis. Pulmonary function tests show FVC 65% predicted and FEV₁/FVC ratio 0.78. What is the most likely diagnosis?

Explanation

## Post-COVID-19 Pulmonary Sequelae: Organizing Pneumonia and Fibrosis ### Clinical Context This patient presents with a **post-acute COVID-19 syndrome** characterized by: - **Timing:** Persistent symptoms 6 weeks after acute infection (beyond typical 2–4 week recovery) - **Negative RT-PCR:** Excludes active viral replication - **Imaging:** Ground-glass opacities with traction bronchiectasis (suggests fibrotic remodeling) - **Pulmonary function:** Restrictive pattern (FVC 65%, FEV₁/FVC 0.78 suggests mixed or restrictive defect) **Key Point:** Post-COVID-19 pulmonary fibrosis is an emerging clinical entity characterized by persistent or progressive interstitial lung disease (ILD) following acute SARS-CoV-2 infection, even in patients with initially mild disease. ### Pathophysiology SARS-CoV-2 causes direct alveolar epithelial and endothelial injury via: 1. **Viral invasion** — ACE2 receptor-mediated entry into type II pneumocytes 2. **Cytokine storm** — IL-6, TNF-α, IL-1β drive inflammatory cell infiltration 3. **Epithelial-mesenchymal transition (EMT)** — infected pneumocytes undergo phenotypic change, promoting fibroblast activation 4. **Aberrant wound healing** — excessive collagen deposition and myofibroblast proliferation 5. **Persistent viral antigen or RNA** — detected in lung tissue weeks after negative nasopharyngeal RT-PCR Histologically, post-COVID fibrosis can present as: - **Organizing pneumonia** — intraluminal fibrosis in small airways (reversible with corticosteroids) - **Usual interstitial pneumonia (UIP) pattern** — subpleural, basilar-predominant fibrosis (less reversible) - **Diffuse alveolar damage (DAD)** — acute phase; resolves or progresses to fibrosis **High-Yield:** The combination of ground-glass opacities + traction bronchiectasis on HRCT is pathognomonic for post-COVID organizing pneumonia or early fibrotic ILD. ### Why This Is the Best Answer - **Negative RT-PCR excludes active infection** — rules out recurrence or reinfection - **Timing (6 weeks post-infection) is classic** — post-COVID fibrosis typically emerges 4–12 weeks after acute illness - **Imaging pattern (GGO + traction bronchiectasis)** — highly specific for organizing pneumonia or fibrotic ILD - **Restrictive PFT pattern** — consistent with ILD, not asthma (which would show obstructive pattern) - **Even mild acute COVID can progress to fibrosis** — severity of acute illness does not predict fibrotic sequelae **Clinical Pearl:** Approximately 20–30% of COVID-19 survivors report persistent respiratory symptoms at 3–6 months, and 10–15% show radiological evidence of ILD on follow-up imaging. ### Management Implications ```mermaid flowchart TD A[Post-COVID respiratory symptoms + abnormal HRCT]:::outcome --> B{Organizing pneumonia pattern?}:::decision B -->|Yes| C[Trial of corticosteroids]:::action B -->|No| D[Assess for UIP pattern]:::decision D -->|UIP features| E[Antifibrotic therapy: pirfenidone or nintedanib]:::action D -->|Nonspecific ILD| F[Monitor with serial PFTs and imaging]:::action C --> G[Repeat imaging at 8-12 weeks]:::action E --> G F --> G G --> H{Improvement?}:::decision H -->|Yes| I[Continue therapy, slow taper]:::action H -->|No| J[Escalate to antifibrotic or refer to ILD specialist]:::action ``` [cite:Lancet Respir Med 2021; Harrison 21e Ch 189]